World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
102
Citations
50148
World Ranking
7540
National Ranking
3935

Overview

Jeffrey W. Clark is affiliated with Harvard University in the United States. Their research primarily focuses on Medicine with a significant concentration in Oncology.

The main fields of study include:

  • Medicine

Subfields of study highlight a more specialized focus:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Surgery
  • Cancer Research
  • Epidemiology

The primary research topics Jeffrey W. Clark explores are diverse within cancer and oncology research:

  • Pancreatic and Hepatic Oncology Research
  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Treatments and Studies
  • Cancer Immunotherapy and Biomarkers
  • Gastric Cancer Management and Outcomes
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Neuroendocrine Tumor Research Advances

Clark has published extensively in several key venues, reflecting a consistent contribution to clinical and cancer research fields. Frequent publication venues include:

  • Journal of Clinical Oncology
  • International Journal of Radiation Oncology*Biology*Physics
  • Clinical Cancer Research
  • The Oncologist
  • Annals of Surgical Oncology

Some of the recent papers associated with Jeffrey W. Clark are:

  • Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration, 2020, Nature Medicine
  • Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer, 2021, Clinical Cancer Research
  • Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial, 2021, Nature Cancer
  • Crizotinib in Patients With MET-Amplified NSCLC, 2021, Journal of Thoracic Oncology
  • Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial, 2023, Nature Medicine

Frequent co-authors collaborating with Jeffrey W. Clark include:

  • David P. Ryan
  • Theodore S. Hong
  • Jill N. Allen
  • Jennifer Y. Wo
  • Aparna R. Parikh

Best Publications

  • Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  • Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

    Christopher G Willett;Yves Boucher;Emmanuelle di Tomaso;Dan G Duda

  • Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Sai Hong I. Ou;Yung Jue Bang;D. Ross Camidge

  • ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

    Kristin Bergethon;Alice T. Shaw;Sai Hong Ignatius Ou;Ryohei Katayama

  • Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

    D. Ross Camidge;Yung Jue Bang;Eunice L. Kwak;A. John Iafrate

  • Lessons from phase III clinical trials on anti-VEGF therapy for cancer

    Rakesh K Jain;Dan G Duda;Jeffrey W Clark;Jay S Loeffler

  • Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

    Alice T. Shaw;Beow Y. Yeap;Benjamin J. Solomon;Gregory J. Riely

  • Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

    James E. Butrynski;David R. D’Adamo;Jason L. Hornick;Paola Dal Cin

  • Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.

    Cristina R. Ferrone;Giovanni Marchegiani;Theodore S. Hong;David P. Ryan

  • Quality of informed consent in cancer clinical trials: a cross-sectional survey

    Steven Joffe;Steven Joffe;E Francis Cook;Paul D Cleary;Jeffrey W Clark

  • Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping

    Darrell R. Borger;Kenneth K. Tanabe;Kenneth C. Fan;Hector U. Lopez

  • Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors

    Matthew H. Kulke;Keith Stuart;Peter C. Enzinger;David P. Ryan

  • Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

    Sai Hong Ignatius Ou;Eunice L. Kwak;Christina Siwak-Tapp;Joni Dy

  • Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study

    Christopher G. Willett;Dan G. Duda;Emmanuelle di Tomaso;Yves Boucher

  • Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors

    Dirk Strumberg;Jeffrey W. Clark;Ahmad Awada;Malcolm J. Moore

  • Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

    Andrew X. Zhu;Dushyant V. Sahani;Dan G. Duda;Emmanuelle di Tomaso

  • Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

    Andrew X. Zhu;Lawrence S. Blaszkowsky;David P. Ryan;Jeffrey W. Clark

  • Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial

    Janet E. Murphy;Jennifer Y. Wo;David P. Ryan;Wenqing Jiang

  • Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.

    Jeffrey W. Clark;Joseph P. Eder;David Ryan;Chetan Lathia

  • Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

    Theodore S. Hong;Jennifer Y. Wo;Beow Y. Yeap;Edgar Ben-Josef

Frequent Co-Authors

David P. Ryan
David P. Ryan Harvard University
Andrew X. Zhu
Andrew X. Zhu Harvard University
Cristina R. Ferrone
Cristina R. Ferrone Harvard University
Rakesh K. Jain
Rakesh K. Jain Harvard University
Christopher G. Willett
Christopher G. Willett Duke University
Dan G. Duda
Dan G. Duda Harvard University
Keith D. Lillemoe
Keith D. Lillemoe Harvard University
Geoffrey I. Shapiro
Geoffrey I. Shapiro Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative pathways in medicine and healthcare can open new doors for aspiring professionals. There are now flexible and accelerated online options for those who wish to move quickly into specialized roles or advance their nursing credentials.

For nurses with a master’s degree seeking faster doctorate-level qualification, the shortest post master's dnp program offers a streamlined route to a Doctor of Nursing Practice. Those seeking a more manageable academic load can find the easiest dnp program online, balancing their studies with professional and personal responsibilities.

Entry-level healthcare positions can also be accessed rapidly through an lpn fast track program—ideal for those looking to start their careers without years of schooling. For those focused on mental health, the pmhnp online programs offer a quick transition to advanced practice roles in psychiatric care.

These programs demonstrate the evolving nature of medical and nursing education, offering more accessible routes for ambitious students in the USA.

Best Scientists Citing Jeffrey W. Clark

Trending Scientists